Loading company
Atrium Therapeutics, Inc.
RNA · Nasdaq · ·
$8.420.0%Sep 29 close
- 1M
- -38.3%
- 6M
- -37.9%
- 1Y
- -80.7%
- 5Y
- -63.8%
Trailing twelve months where a flow is involved, latest reported balance where it is not.
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each quarter on its own, so seasonal highs and lows are visible.
$3MQ2 2026-84.7%
Everything the company sold, before any costs. Each quarter on its own, so seasonal highs and lows are visible.
-$22.28MQ2 2026-30.0%
Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. Each quarter on its own, so seasonal highs and lows are visible.
-$20.19MQ2 2026-21.4%
What was left after every cost, including tax. Each quarter on its own, so seasonal highs and lows are visible.
-$3.96MQ2 2026+88.1%
Cash left over after running and maintaining the business. Each quarter on its own, so seasonal highs and lows are visible.
-$1.18Q2 2026-21.6%
The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each quarter on its own, so seasonal highs and lows are visible.
17.11MQ2 20260.0%
How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each quarter on its own, so seasonal highs and lows are visible.
Everything above comes from Atrium Therapeutics, Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.
Not reported by this filer: Cost of Revenue, Gross Profit, Interest Expense, Income Tax Expense, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Inventory, Receivables, Long-term Debt (noncurrent), Long-term Debt (current), Short-term Borrowings, Borrowings (total), Operating Lease (noncurrent), Operating Lease (total), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), Dividends paid, Amortization of Intangibles, and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
RNA · Nasdaq · ·
$8.420.0%Sep 29 close